Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Homeopatia

Home > Pesquisa > ()
XML
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Investigación electrónica del tratamiento de la hiperprolactinemia en Brasil: endocrinólogos contra ginecólogos / Electronic survey of management of hyperprolactinemia in Brazil: Endocrinologists versus gynecologists

dos Santos Nunes, Vania; Vicentini, Henrique Claudio; Padovani, Carlos Roberto; Nogueira, Celia Regina; Vilar, Lucio.
Rev. argent. endocrinol. metab ; 54(3): 124-129, set. 2017. graf, tab
Artigo em Inglês | LILACS | ID: biblio-957977
Hyperprolactinemia is a frequent condition in clinical practice, responsible for 20-25% of secondary amenorrhea cases. We performed an electronic survey among members of the Brazilian Society of Metabolism and Endocrinology (SBEM) and the Brazilian Federation of Association of Gynecology and Obstetrics (FEBRASGO) to assess diagnostic and therapeutic preferences for management of hyperprolactinemia. Electronic addresses of SBEM and FEBRASGO members were obtained from the directories of these societies, and these members were invited, through electronic messages (e-mail), to answer an online questionnaire that included 10 questions about the treatment of micro and macropro-lactinomas, maximum dose of dopamine agonist, how to exclude primary hypothyroidism and macroprolactinemia, hyperprolactinemia and pregnancy. We received responses to the questionnaire by e-mail from 521 SBEM members and 233 FEBRASGO members. The results of this survey demonstrate that there are many area of agreement between SBEM and FEBRASGO members and most of their responses follow the latest Endocrine Society Guideline. Relative to a survey performed several years ago, our findings show that SBEM members have incorporated some of latest recommendations in this field. The principal issues of concern for both groups are duration of dopamine agonist treatment for patients with microprolactinoma and dopamine agonist withdrawal during pregnancy.
Biblioteca responsável: AR1.2
Selo DaSilva